ArticleNeuropsychiatric disease and treatment2025
Prevalence, Diagnosis, and Treatment of Generalized Anxiety Disorder in Working Individuals: A Cross-Sectional Study Using Health Claims and Survey Data in Japan.
Article in Neuropsychiatric disease and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Generalized anxiety disorder (GAD) is a common anxiety disorder, and in Japan is poorly understood to be a serious condition among medical practitioners and the general public. This study was, therefore, conducted targeting individuals with probable GAD, to estimate the prevalence of probable GAD as the primary outcome, and to assess medical consultation behavior, diagnosis, treatment, quality of life (QOL), severity of depression symptoms, and work productivity as secondary outcomes. Patients and Methods: This was conducted as a cross-sectional study focusing on individuals with probable GAD, using a database comprising medical claims data from May 2022 to November 2022, and linked survey data collected in November 2022, provided by DeSC Healthcare, Inc. (DeSC). Probable GAD was defined as a score of ≥10 in the Generalized Anxiety Disorder 7-item questionnaire (GAD-7). Secondary endpoints were assessed from claims data and online survey data. Results: In the study population (n = 18,995), the overall prevalence of probable GAD was 6.4%. Among the probable GAD group, a total of 89.7% individuals received medical consultation; and among this population, 15.8% of individuals consulted with a psychiatric specialist. In the probable GAD group, the most common psychiatric disorder diagnoses were sleep disorders, mood disorders other than bipolar disorder, and somatoform disorders. The most commonly prescribed drugs were antianxiety drugs, followed by hypnotics, and antidepressants. QOL and work productivity were lower in the probable GAD group than the non-probable GAD group; whereas, severity of depression was higher in the probable GAD group. Conclusion: The study findings showed a high prevalence of probable GAD, low consultation behavior, and clarified the diagnosis and treatment status for GAD. These findings highlight the need to raise awareness of GAD among both physicians and patients, leading to appropriate consultation behavior, diagnosis, and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.